Benzinga | Jul 30, 2021 09:05AM EDT

Bristol Myers' Opdivo Scores European Approval As Adjuvant Treatment For Gastric Cancer

* The European Commission (EC) has approved Bristol Myers Squibb & Co's (NYSE:BMY) Opdivo (nivolumab) as adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer.

* The approval covers patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).

* The EC's decision is based on results from the Phase 3 CheckMate -577 trial, which demonstrated that treatment with Opdivo following neoadjuvant CRT and complete surgical resection doubled the primary endpoint of disease-free survival, compared to placebo in the all-randomized population.

* Price Action: BMY shares closed at $68.15 on Thursday.

* Related content: Benzinga's Full FDA Calendar.